ABCL Q1 2026 Earnings
Reported May 11, 2026 at 4:11 PM ET · SEC Source
Q1 26 EPS
$-0.14
BEAT +29.11%
Est. $-0.20
Q1 26 Revenue
$8.3M
BEAT +42.49%
Est. $5.8M
vs S&P Since Q1 26
+18.7%
BEATING MARKET
ABCL +18.0% vs S&P -0.7%
Market Reaction
Did ABCL Beat Earnings? Q1 2026 Results
AbCellera Biologics delivered a sharply stronger-than-expected first quarter for fiscal 2026, beating on both the top and bottom lines as revenue nearly doubled year-over-year. The Vancouver-based antibody company posted revenue of $8.31 million, a 9… Read more AbCellera Biologics delivered a sharply stronger-than-expected first quarter for fiscal 2026, beating on both the top and bottom lines as revenue nearly doubled year-over-year. The Vancouver-based antibody company posted revenue of $8.31 million, a 96.3% increase from the year-ago period and well ahead of the $5.84 million consensus estimate, a 42.49% beat driven primarily by research fees. The adjusted loss per share of $0.14 came in meaningfully better than the $0.20 analysts had anticipated, a 29.11% positive surprise, even as R&D expenses climbed to $46.66 million to support advancing clinical programs. The quarter's most significant catalyst was positive interim Phase 1 data for ABCL635, its potential non-hormonal antibody treatment for menopausal vasomotor symptoms, which showed a favorable tolerability profile and no liver toxicity, prompting advancement into a Phase 2 study with topline results expected in Q3 2026. Analysts lifted their consensus price target to $10.14 following the results. AbCellera ended the quarter with approximately $655 million in total available liquidity, which it expects to fund execution of its pipeline strategy through key 2026 and 2027 data readouts.
Key Takeaways
- • Research fees nearly doubled year-over-year to $8.1 million from $4.1 million
- • SG&A expenses reduced by $6.7 million year-over-year
- • Positive ABCL635 Phase 1 interim clinical data advancing program forward
ABCL Forward Guidance & Outlook
AbCellera's 2026 priorities center on advancing its pipeline to key data readouts: ABCL635 Phase 2 topline results expected in Q3 2026, ABCL575 Phase 1 topline results expected in Q4 2026, continuing IND-enabling activities for ABCL688 and ABCL386, and selecting at least one additional development candidate. The company aims to set up for three additional IND submissions in 2027. In 2027, potential catalysts include late-stage development of ABCL635 in menopausal VMS, initiation of Phase 2 studies of ABCL635 in oncology-related VMS, options for further development or out-licensing of ABCL575, and IND submissions and initiation of Phase 1/2 studies for ABCL688 and ABCL386. The company expects its approximately $655 million in total available liquidity to fund execution of its strategy.
ABCL YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
ABCL Revenue by Segment
With YoY comparisons, source: SEC Filings
“We are excited to share interim Phase 1 data that show ABCL635 achieved robust NK3R target engagement at doses that were well-tolerated in healthy volunteers and a pharmacokinetic profile that may support a once monthly dosing regimen. We look forward to the efficacy readout from the Phase 2 data in Q3, which we believe will be highly de-risking for the program.”
— Carl Hansen, Q1 2026 Earnings Press Release
ABCL Earnings Trends
ABCL vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
ABCL EPS Trend
Earnings per share: estimate vs actual
ABCL Revenue Trend
Quarterly revenue: estimate vs actual
ABCL Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $-0.20 | $-0.14 | +29.11% | $8.3M | +42.49% |
| Q4 25 BEAT FY | $-0.18 | $-0.03 | +83.33% | $44.9M | +569.55% |
| FY Full Year | — | $-0.49 | — | $75.1M | — |
| Q3 25 MISS | $-0.16 | $-0.19 | -17.28% | $9.0M | +41.40% |
| Q2 25 BEAT | $-0.16 | $-0.12 | +25.00% | $17.1M | +173.69% |